Key Drivers and Opportunities in the Focal Segmental Glomerulosclerosis Drugs Market: Insights into Trends and Growth
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What Long-Term Growth Rate is Expected for the Focal Segmental Glomerulosclerosis Drugs Market Between 2025 and 2034?
The market for drugs treating focal segmental glomerulosclerosis has seen robust growth in the past few years. It is projected to increase from $15.77 billion in 2024 to $17.08 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%. This historic growth trend is due to factors such as the increased prevalence of the disease, higher demands for new treatment methods, a rising interest from the pharmaceutical industry, and enhanced government backing.
The market size for drugs treating focal segmental glomerulosclerosis is set to experience significant growth over the coming years. It is projected to increase to $24.87 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.8%. Factors driving this growth during the forecast period include research and development spending, increasing healthcare costs, heightened awareness and diagnosis, an aging population, as well as government initiatives and funding. Key trends during this forecast period involve technological progress in medicine discovery and development, the growth of the clinical trials pipeline, enhanced drug reimbursement schemes for focal segmental glomerulosclerosis treatments, and the expansion of company research facilities.
What Market Dynamics Are Playing a Key Role in Accelerating the Growth of the focal segmental glomerulosclerosis drugs Market?
The escalating incidents of kidney infections are anticipated to stimulate the expansion of the focal segmental glomerulosclerosis (FSGS) drugs market. Pyelonephritis, a severe form of urinary tract infection (UTI) affecting one or both kidneys, is driving the need for FSGS drugs. These specialized treatments for kidney diseases offer several positives in terms of managing the ailment and enhancing kidney performance by reducing proteinuria, slowing kidney damage progression, and enhancing the life quality of patients afflicted with kidney-related ailments. In July 2022, The Centers for Disease Control and Prevention, part of the US Department of Health and Human Services, reported about 15% (37 million) of the US population dealing with kidney diseases. In 2021, there was a 12% prevalence rate for individuals within the 45–64 age bracket and a 6% rate for those aged between 18 and 44. Therefore, the burgeoning rise in kidney infections acts as a driver for the focal segmental glomerulosclerosis (FSGS) market. The integral role of increasing healthcare expenditures in propelling the growth of the Focal Segmental Glomerulosclerosis (FSGS) Drugs Market:
Explore Comprehensive Insights Into The Global Focal Segmental Glomerulosclerosis Drugs Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12866&type=smp
What Are the Key Firms That Are Driving Transformation in the Focal Segmental Glomerulosclerosis Drugs Market?
Major companies operating in the focal segmental glomerulosclerosis drugs market are:
• Pfizer Inc._x000D_
• Johnson and Johnson Ltd._x000D_
• F. Hoffmann-La Roche AG_x000D_
• Bayer AG_x000D_
• Novartis AG_x000D_
What Current Trends in the Focal Segmental Glomerulosclerosis Drugs Market Should Industry Players Pay Attention To?
Key players in the focal segmental glomerulosclerosis (FSGS) market are progressively centering their efforts on product progression and novelty, aiming to offer dependable products to their clients and fortify their stand in the market. To illustrate, Travere Therapeutics, a biopharmaceutical firm based in the US, introduced FILSPARI, a medication for focal segmental glomerulosclerosis (FSGS) in February 2023. This product was sanctioned by the Food and Drug Administration (FDA), a federal agency in the US. FILSPARI is an orally taken medicine for addressing IgA nephropathy (IgAN) and is distinguished as the first and sole non-immunosuppressive treatment to reduce proteinuria in IgAN, a seldom-seen kidney ailment. Furthermore, both the US and Europe have granted FILSPARI orphan drug status for the treatment of IgAN and focal segmental glomerulosclerosis (FSGS).
Secure Your Global Focal Segmental Glomerulosclerosis Drugs Market Report Now for Fast and Efficient Delivery!
What Are the Strategic Segments Comprising the Focal Segmental Glomerulosclerosis Drugs Market and Their Growth Contributions?
The focal segmental glomerulosclerosis drugs market covered in this report is segmented –
1) By Type: Losmapimod, SHP-627, Sparsentan, TM-5484, Other Types
2) By Treatment: Corticosteroids, Immunosuppressive Drugs, Angiotensin Converting Enzymes (ACE) Inhibitors, A.R. Blockers, Diuretics, Other Treatments
3) By Route of Administration: Oral, Parenteral
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
What Regions Are Driving Expansion in the Focal Segmental Glomerulosclerosis Drugs Market?
North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2024. The regions covered in the focal segmental glomerulosclerosis (FSGS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does the Definition of the Focal Segmental Glomerulosclerosis Drugs Market Include?
Focal segmental glomerulosclerosis (FSGS) is a rare type of kidney disease that causes scarring in the kidneys’ filters. Focal segmental glomerulosclerosis (FSGS) drugs refer to medications used to treat and manage the progression of the disease.
Browse Through More Similar Reports By The Business Research Company:
Kidney Dialysis Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/kidney-dialysis-global-market-report
Artificial Kidney Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/artificial-kidney-global-market-report
Diabetic Kidney Disease Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
